Posts by: Margarida Azevedo

Margarida Azevedo

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

April 18, 2016April 18, 2016

Gene Editing as Promising Approach to Stop Cancer Cell Evasion

News

Researchers at England’s University College of London, led by Prof. Karl Peggs and Dr. Sergio Quezada, have inactivated an important immune-inhibitory pathway through an advanced gene-editing technique, demonstrating this approach holds promise for increased ... Read more

April 5, 2016April 5, 2016

Certain Oncology Agents Enhance Immunotherapy Response in Lung Cancer Mouse Models

News

A specific class of FDA-approved oncology agents called histone deacetylase (HDAC) inhibitors proved effective to induce T-cell responses in tumors, in conjugation with immunotherapeutic PD-1 antibodies, decreasing the growth of lung tumors ... Read more

March 29, 2016March 29, 2016

Many Tumor-Targeted Cancer Therapies Are Suppressing Positive T-Cell Immune Responses, Researchers Say

News

Researchers at Philadelphia’s Wistar Institute investigating the effects of tumor-targeted therapies on the immune system found that many of these agents, such as FDA-approved trametinib, actually suppress the activity of cancer-fighting ... Read more

March 28, 2016March 28, 2016

Cancer Immunotherapies and Radiation Form Powerful Combination Therapy, Researchers Say

News

Cancer immunotherapy relies on the stimulation of the patient’s own immune system for an effective and lasting anti-tumor response, targeting and eliminating cancer cells. Both the research and clinical communities believe ... Read more

March 15, 2016March 15, 2016

Oncogene’s Steps in Helping Tumors Evade Immune System Detailed in Study

News

Stanford University School of Medicine researchers shed light on how oncogenes participate in the genesis and progression of cancer, helping tumor cells evade immune responses. The team studied the Myc oncogene and ... Read more

March 9, 2016March 9, 2016

New Discovery in Cancer Tumor Antigens Opens Door for Patient-Targeted Immunotherapy

News

Researchers at University College London (UCL) in England have discovered antigen diversity on the surface of cancer cells that influences immune system recognition and can be used to improve cancer immunotherapies targeting complex ... Read more

March 7, 2016March 7, 2016

Cell-Based Immunotherapy Vaccine Improves Survival in Mice Models of Aggressive Brain Cancer

News

Belgium’s KU Leuven researchers have developed an improved cell-based immunotherapy to treat high-grade glioma, one of the most aggressive types of brain cancer. The dendritic cell-based vaccine therapy was able to greatly ... Read more

February 29, 2016February 29, 2016

Immunotherapy Potential of Diabetes Drug, Metformin, Explained and Strongly Supported in Study

News

Japanese research into the anti-cancer effects of metformin, a prescribed drug for type 2 diabetes, indicates that the drug’s mechanism is immune-mediated and that it works by preventing the apoptosis and exhaustion of key ... Read more

February 22, 2016February 22, 2016

Cancer Immunotherapy in Children Could See Improvements with Earlier Lineage T-Cells

News

Pediatric oncologists from the Children’s Hospital of Philadelphia (CHOP) have investigated techniques to improve and expand a novel personalized cell therapy to treat children with acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL). ... Read more

February 17, 2016February 18, 2016

Oncologist Reports ‘Dramatic’ Anti-Cancer Effect Seen in New T-cell Immunotherapy

News

Dr. Stanley Riddell, an oncologist and immunotherapy researcher at the Fred Hutchinson Cancer Research Center in Seattle, recently presented “dramatic” results from his adoptive T-cell strategy to fight cancer at the ... Read more